基底样乳腺癌中的非编码RNA生物标志物
本文综述了非编码RNA(ncRNA)在基底样乳腺癌(BLBC)中的研究进展。ncRNA在体液中稳定且表达具有亚型特异性,可作为微创生物标志物用于早期检测、预后预测和疗效监测,并具有治疗潜力,但面临检测标准化和递送优化等挑战。
要点
- ncRNA在体液中稳定且亚型特异,有望成为BLBC微创生物标志物。
- ncRNA参与BLBC关键致癌与抑癌通路,具诊断和预后价值。
- ncRNA治疗可克服耐药,但检测标准化与递送优化仍是挑战。
核心结论
- ncRNA在体液中稳定且表达具亚型特异性,是BLBC有前景的微创生物标志物。
- ncRNA基于的治疗策略可克服耐药并改善疗效,但需解决检测标准化与递送优化问题。
研究设计与样本
- 综述整合了ncRNA在基底样乳腺癌中的生物学、生物标志物及治疗应用的最新进展。
主要发现
- miRNA、lncRNA、siRNA和circRNA等ncRNA是BLBC肿瘤发生和进展的关键调控因子。
- ncRNA的亚型特异性表达和体液稳定性支持其作为微创生物标志物。
- ncRNA生物标志物可用于早期检测、预后预测和疗效监测。
临床怎么用
- 可探索将ncRNA作为BLBC早期检测、预后分层和疗效监测的微创生物标志物。
- ncRNA治疗策略有望用于克服耐药和改善疗效,但需关注检测标准化与递送优化。
局限性
- ncRNA检测标准化和递送优化仍是临床转化的当前挑战。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Basal-like breast cancer (BLBC) is a highly aggressive molecular subtype characterized by poor prognosis and limited targeted treatment options. Clinicians face challenges in early diagnosis and precise prognostic stratification, necessitating the discovery of novel biomarkers and therapeutic targets. Non-coding RNAs (ncRNAs), including microRNAs (miRNAs), long non-coding RNAs (lncRNAs), small interfering RNAs (siRNAs), and circular RNAs (circRNAs), have emerged as crucial regulators of breast luminal B cancer (BLBC) tumorigenesis and progression. Their subtype-specific expression and remarkable stability in body fluids make them promising candidates for minimally invasive biomarkers in clinical chemistry, enabling the early detection, prediction of prognosis, and monitoring of therapeutic response. Additionally, ncRNA-based therapeutics offer innovative strategies to overcome resistance and improve treatment efficacy. This review comprehensively synthesises the latest advances in understanding non-coding RNA (ncRNA) biology in breast luminal B-like cancer (BLBC), focusing on their roles in key oncogenic and tumour-suppressive pathways. We highlight the translational potential of ncRNAs as diagnostic and prognostic biomarkers and discuss emerging therapeutic applications alongside current challenges such as assay standardisation and delivery optimisation. The novelty of this review lies in its integrative approach, bridging molecular mechanisms with clinical implications to guide future research and clinical translation. We aim to provide a critical resource that supports the development of ncRNA-based precision medicine approaches to improve the management and outcomes of patients with basal-like breast cancer.
引用
- Ali H, Khan NH, Cano D, et al. Non-coding RNA biomarkers in basal-like breast cancer. Clin Chim Acta. 2025. PMID: 40456356. doi:10.1016/j.cca.2025.120408
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。